论文部分内容阅读
2012年5月,美国FDA批准更新了Celgene公司的来那度胺(lenalidomide/Revlimid)标签中的安全性信息,主要加入了该药治疗新近诊出的多发性骨髓瘤患者会提高他们发展第二种原发性肿瘤(特别是急性髓细胞性白血病、骨髓增生异常综合征和何杰金淋巴瘤)风险的相关警告内容和注意事项。
In May 2012, the US FDA approved the update of Celgene’s safety information on the lenalidomide / Revlimid label, which was added primarily to the treatment of newly diagnosed multiple myeloma patients who would improve their second Related types of cautions and warnings about the risk of primary tumors (especially acute myelogenous leukemia, myelodysplastic syndrome and Hodgkin’s lymphoma).